Table 1.
Patient characteristics
| Characteristic | Total (n=11) |
|---|---|
| Age, years | |
| Median (range) | 59.0 (43–78) |
| Gender, n (%) | |
| Female | 4 (36) |
| Race, n (%) | |
| Caucasian | 10 (91) |
| Black | 1 (9) |
| Ethnicity, n (%) | |
| Non-Hispanic | 11 (100) |
| Cancer type, n (%) | |
| Lung, adenocarcinoma | 5 (45) |
| Lung, squamous uveal | 3 (27) |
| Melanoma | 3 (27) |
| AJCC stage, n (%) | |
| IV | 11 (100) |
| BMI, mg/m2 | |
| Mean (SD) | 27.7 (4.2) |
| Albumin, g/dL | |
| Mean (SD) | 4.1 (0.5) |
| Prior PD-1 or PD-L1 mAb, n (%) | |
| Yes | 6 (55) |
| No | 5 (45) |
| Cohort, mg; n (%) | |
| 2.5 | 3 (27) |
| 5 | 3 (27) |
| 10 | 3 (27) |
| 15* | 2 (18) |
| Prior lines of systemic therapy | |
| Median, range | 4 (2–7) |
| Prior radiation, n (%) | |
| Yes | 8 (73) |
| No | 3 (27) |
| Prior brain metastases, n (%) | |
| Yes | 5 (45) |
| No | 6 (55) |
Notes: All percentages are rounded and therefore may not exactly sum to one. Stage is assessed at the date of treatment.
*
Dose level completed in two subjects.
Abbreviations: AJCC, American Joint Committee on Cancer; BMI, body mass index; mAb, monoclonal antibody; PD-1, programmed cell death protein 1.